Patents by Inventor Christoph Ullmer

Christoph Ullmer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibody that binds to VEGF-A and ANG2 and methods of use
    Patent number: 11732036
    Abstract: The present invention relates to anti-VEGF-A/anti-ANG2 antibodies, e.g. in the form of a bispecific Fab fragment, and methods of using the same.
    Type: Grant
    Filed: September 3, 2021
    Date of Patent: August 22, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Roland Beckmann, Sebastian Fenn, Guido Hartmann, Sabine Imhof-Jung, Kristian Hobolt-Jensen, Joerg Moelleken, Michael Molhoj, Christian Schantz, Janina Speck, Christoph Ullmer, Barbara Weiser
  • ANTIBODY THAT BINDS TO VEGF-A AND ANG2 AND METHODS OF USE
    Publication number: 20220073599
    Abstract: The present invention relates to anti-VEGF-A/anti-ANG2 antibodies, e.g. in the form of a bispecific Fab fragment, and methods of using the same.
    Type: Application
    Filed: September 3, 2021
    Publication date: March 10, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Roland Beckmann, Sebastian Fenn, Guido Hartmann, Sabine Imhof-Jung, Kristian Hobolt-Jensen, Joerg Moelleken, Michael Molhoj, Christian Schantz, Janina Speck, Christoph Ullmer, Barbara Weiser
  • Bicyclic compounds as dual ATX/CA inhibitors
    Patent number: 10889588
    Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R9, Y, W, m, n, p and q are as defined herein, compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: June 1, 2020
    Date of Patent: January 12, 2021
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Jerome Hert, Daniel Hunziker, Patrizio Mattei, Markus Rudolph, Petra Schmitz, Christoph Ullmer
  • BICYCLIC COMPOUNDS AS DUAL ATX/CA INHIBITORS
    Publication number: 20200291038
    Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R9, Y, W, m, n, p and q are as defined herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: June 1, 2020
    Publication date: September 17, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Jerome HERT, Daniel HUNZIKER, Patrizio MATTEI, Markus RUDOLPH, Petra Schmitz, Christoph ULLMER
  • Bicyclic compounds as dual ATX/CA inhibitors
    Patent number: 10738053
    Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R9, Y, W, m, n, p and q are as defined herein, compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: August 11, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Jerome Hert, Daniel Hunziker, Patrizio Mattei, Markus Rudolph, Petra Schmitz, Christoph Ullmer
  • BICYCLIC COMPOUNDS AS DUAL ATX/CA INHIBITORS
    Publication number: 20200223854
    Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, Y, W, m, n, p and q are as defined herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: March 27, 2020
    Publication date: July 16, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Patrick DI GIORGIO, Jerome HERT, Daniel HUNZIKER, Patrizio MATTEI, Markus RUDOLPH, Petra SCHMITZ, Christoph ULLMER
  • DIAZASPIROCYCLOALKANE AND AZASPIROCYCLOALKANE
    Publication number: 20200207769
    Abstract: Compounds having the general formula (I) wherein R1, R2, Y and W are as described herein, compositions including the compounds and methods of using the compounds as autotaxin inhibitors.
    Type: Application
    Filed: March 12, 2020
    Publication date: July 2, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Daniel HUNZIKER, Patrizio MATTEI, Harald MAUSER, Marco PRUNOTTO, Christoph ULLMER
  • Bicyclic compounds as dual ATX/CA inhibitors
    Patent number: 10647719
    Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, Y, W, m, n, p and q are as defined herein, compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: May 12, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Patrick Di Giorgio, Jerome Hert, Daniel Hunziker, Patrizio Mattei, Markus Rudolph, Petra Schmitz, Christoph Ullmer
  • Diazaspirocycloalkane and azaspirocycloalkane
    Patent number: 10633384
    Abstract: Compounds having the general formula (I) wherein R1, R2, Y and W are as described herein, compositions including the compounds and methods of using the compounds as autotaxin inhibitors.
    Type: Grant
    Filed: October 13, 2016
    Date of Patent: April 28, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Daniel Hunziker, Patrizio Mattei, Harald Mauser, Marco Prunotto, Christoph Ullmer
  • 3-amino-pyridines as GPBAR1 agonists
    Patent number: 10385022
    Abstract: This invention relates to novel 3-aminopyridines of the formula wherein B1, B2 and R1 to R6 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are GPBAR1 agonists and can be used as medicaments for the treatment of diseases such as type II diabetes.
    Type: Grant
    Filed: February 6, 2015
    Date of Patent: August 20, 2019
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Caterina Bissantz, Henrietta Dehmlow, Shawn David Erickson, Prabha Saba Karnachi, Kyungjin Kim, Rainer E. Martin, Patrizio Mattei, Ulrike Obst Sander, Sherrie Lynn Pietranico-Cole, Hans Richter, Christoph Ullmer
  • Radiolabeled cannabinoid receptor 2 ligand
    Patent number: 10227308
    Abstract: The present invention relates to a compound of formula (I) wherein R1 is defined as in the description and in the claims. The compound of formula (I) can be used as radiolabeled ligand.
    Type: Grant
    Filed: February 27, 2017
    Date of Patent: March 12, 2019
    Assignees: HOFFMANN-LA ROCHE INC., EIDGENÖSSISCHE TECHNISCHE HOCHSCHULE ZÜRCIH, UNIVERSITÄT ZÜRICH
    Inventors: Simon M. Ametamey, Juergen Fingerle, Luca Gobbi, Uwe Grether, Ahmed Haider, Thomas Hartung, Linjing Mu, Leo Nicholls, Mark Rogers-Evans, Christoph Ullmer
  • NEW BICYCLIC COMPOUNDS AS DUAL ATX/CA INHIBITORS
    Publication number: 20180215765
    Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, Y, W, m, n, p and q are as defined herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: March 23, 2018
    Publication date: August 2, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Patrick Di Giorgio, Jerome Hert, Daniel Hunziker, Patrizio Mattei, Markus Rudolph, Petra Schmitz, Christoph Ullmer
  • BICYCLIC COMPOUNDS AS DUAL ATX/CA INHIBITORS
    Publication number: 20180208601
    Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R9, Y, W, m, n, p and q are as defined herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: March 23, 2018
    Publication date: July 26, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Jerome Hert, Daniel Hunziker, Patrizio Mattei, Markus Rudolph, Petra Schmitz, Christoph Ullmer
  • RADIOLABELED CANNABINOID RECEPTOR 2 LIGAND
    Publication number: 20170166534
    Abstract: The present invention relates to a compound of formula (I) wherein R1 is defined as in the description and in the claims. The compound of formula (I) can be used as radiolabeled ligand.
    Type: Application
    Filed: February 27, 2017
    Publication date: June 15, 2017
    Applicants: Hoffmann-La Roche Inc., EIDGENÖSSISCHE TECHNISCHE HOCHSCHULE ZÜRICH, UNIVERSITÄT ZÜRICH
    Inventors: Simon M. Ametamey, Juergen Fingerle, Luca Gobbi, Uwe Grether, Ahmed Haider, Thomas Hartung, Linjing Mu, Leo Nicholls, Mark Rogers-Evans, Christoph Ullmer
  • NEW DIAZASPIROCYCLOALKANE AND AZASPIROCYCLOALKANE
    Publication number: 20170029425
    Abstract: Compounds having the general formula (I) wherein R1, R2, Y and W are as described herein, compositions including the compounds and methods of using the compounds as autotaxin inhibitors.
    Type: Application
    Filed: October 13, 2016
    Publication date: February 2, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Daniel Hunziker, Patrizio Mattei, Harald Mauser, Marco Prunotto, Christoph Ullmer
  • Diazaspirocycloalkane and azaspirocycloalkane
    Patent number: 9493486
    Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, Y and W are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: December 12, 2014
    Date of Patent: November 15, 2016
    Assignee: Hoffmann-La Roches Inc.
    Inventors: Daniel Hunziker, Patrizio Mattei, Harald Mauser, Marco Prunotto, Christoph Ullmer
  • NOVEL PYRIDINE DERIVATIVES
    Publication number: 20160137606
    Abstract: The invention relates to a compound of formula (I) wherein R1 to R4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: January 21, 2016
    Publication date: May 19, 2016
    Inventors: Caterina Bissantz, Uwe Grether, Paul Hebeisen, Atsushi Kimbara, Qingping Liu, Matthias Nettekoven, Marco Prunotto, Stephan Roever, Mark Rogers-Evans, Tanja Schulz-Gasch, Christoph Ullmer, Zhiwei Wang, Wulun Yang
  • Pyridine derivatives as agonists of the CB2 receptor
    Patent number: 9321727
    Abstract: The invention relates to a compound of formula (I) Wherein R1, R2, R3 and R4 are defined as in the description and in the claims. The said compounds of the invention are preferential agoniste of the Carsonabinocid Receptor 2 and thus useful as medicaments and may be used in treatment of chronic pain, atherosclerosis, ischemic/reperfusion injury and other related diseases. A representative compound of this invention is 6-cyclopropylmethoxy-5-(tetrahydro-pyradine-2-carboxglic acid [1-methyl-1-(5-methyl-(1,2,4]oxadiazol-3-yl)-ethyl)-amide.
    Type: Grant
    Filed: June 1, 2012
    Date of Patent: April 26, 2016
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Caterina Bissantz, Uwe Grether, Paul Hebeisen, Atsushi Kimbara, Qingping Liu, Matthias Nettekoven, Marco Prunotto, Stephan Roever, Mark Rogers-Evans, Tanja Schulz-Gasch, Christoph Ullmer, Zhiwei Wang, Wulun Yang
  • Pyridine derivatives as agonists of the CB2 receptor
    Patent number: 9290451
    Abstract: The invention relates to a compound of formula (I) Wherein R1, R2, R3 and R4 are defined as in the description and in the claims. The said compounds of the invention are preferential agoniste of the Carsonabinocid Receptor 2 and thus useful as medicaments and may be used in treatment of chronic pain, atherosclerosis, ischemic/reperfusion injury and other related diseases. A representative compound of this invention is 6-cyclopropylmethoxy-5-(tetrahydro-pyradine-2-carboxglic acid [1-methyl-1-(5-methyl-(1,2,4]oxadiazol-3-yl)-ethyl)-amide.
    Type: Grant
    Filed: June 1, 2012
    Date of Patent: March 22, 2016
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Caterina Bissantz, Uwe Grether, Paul Hebeisen, Atsushi Kimbara, Qingping Liu, Matthias Nettekoven, Marco Prunotto, Stephan Roever, Mark Rogers-Evans, Tanja Schulz-Gasch, Christoph Ullmer, Zhiwei Wang, Wulun Yang
  • 3-AMINO-PYRIDINES AS GPBAR1 AGONISTS
    Publication number: 20150152058
    Abstract: This invention relates to novel 3-aminopyridines of the formula wherein B1, B2 and R1 to R6 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are GPBAR1 agonists and can be used as medicaments for the treatment of diseases such as type II diabetes.
    Type: Application
    Filed: February 6, 2015
    Publication date: June 4, 2015
    Inventors: Caterina Bissantz, Henrietta Dehmlow, Shawn David Erickson, Prabha Saba Karnachi, Kyungjin Kim, Rainer E. Martin, Patrizio Mattei, Ulrike Obst Sander, Sherrie Lynn Pietranico-Cole, Hans Richter, Christoph Ullmer